peramivr given another 55m, page-9

I missied one important point

iv/ Go it alone using DS manufacturing on LANI for ROW stockpiling.

LANI is the only near market (ROW) next gen antiviral in this space. Biota management have been unable to sell this concept to US grant agencies, potential licensees and possibly, most importantly, the media as well as potential users - WHO and strategic world medical scientists.

Let's get this show on the road.

Again, let's get a serious boss in place now, let's immediately get domiciled in the US (if that requires a takeover, make it happen) and let's show HHS/BARDA that this is happening.